dc.contributor.author | Samuel, M | |
dc.contributor.author | Kisely, S | |
dc.contributor.author | Rhys-Gill, E | |
dc.contributor.author | Roberts, A | |
dc.contributor.author | Addis, S | |
dc.contributor.author | Alderton, D | |
dc.contributor.author | Preston, N | |
dc.contributor.author | Castle, D | |
dc.date.accessioned | 2017-05-03T11:46:09Z | |
dc.date.available | 2017-05-03T11:46:09Z | |
dc.date.issued | 2003 | |
dc.date.modified | 2010-08-16T06:48:18Z | |
dc.identifier.issn | 0963-8237 | |
dc.identifier.doi | 10.1080/09638230310001603573 | |
dc.identifier.uri | http://hdl.handle.net/10072/33474 | |
dc.description.abstract | Objectives: To compare the 12-month clinical outcome of patients attending a depot clinic who were changed to oral atypical antipsychotic medication, with those who remained on depot preparations. Method: A systematic review of the case records of all patients aged between 18 and 65 attending the depot clinic at Fremantle Hospital, Western Australia. Results: The records of 72 patients were identified (mean age 43.3 years; duration of illness 8.5 years; 37% female); 71% had schizophrenia. Twenty-five patients were successfully switched to an oral atypical antipsychotic (34%), 34 controls remained on a depot (47%), five were managed on a combination of a depot and an atypical, and eight returned to depot medication after a trial of an oral atypical. At 12 month follow-up, patients on oral atypicals showed significant improvement on the CGI (z=-2.57, p=0.01), less akathisia (z=-2.12, p=0.03), and reduced use of antiparkinsonian medication (z=-1.97, p=0.04); these changes were not mirrored in the controls. On multivariate analysis, being on an atypical agent was an independent predictor of improved outcome as measured by the CGI scale (t=-2.1, p=0.04), but also weight gain (t=-2.9, p=0.006). Conclusions: This retrospective survey reveals that a proportion of patients on depot antipsychotic medication can successfully be changed to oral atypical agents, with enhanced clinical outcomes. Declaration of interest: This study was supported by an investigator-initiated grant to SK and DC from Janssen Cilag. DC has received honoraria, travel support, and other grant funding from both Janssen Cilag and Eli Lilly. | |
dc.description.peerreviewed | Yes | |
dc.description.publicationstatus | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Taylor & Francis | |
dc.publisher.place | UK | |
dc.relation.ispartofpagefrom | 513 | |
dc.relation.ispartofpageto | 519 | |
dc.relation.ispartofissue | 5 | |
dc.relation.ispartofjournal | Journal of Mental Health | |
dc.relation.ispartofvolume | 12 | |
dc.subject.fieldofresearch | Clinical sciences | |
dc.subject.fieldofresearch | Clinical sciences not elsewhere classified | |
dc.subject.fieldofresearchcode | 3202 | |
dc.subject.fieldofresearchcode | 320299 | |
dc.title | Switching patients to atypical oral antipsychotics: A retrospective audit of depot clinic attenders | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
gro.date.issued | 2003 | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Kisely, Steve R. | |